Capital Analysts LLC Has $13.39 Million Stock Position in Becton, Dickinson and Company $BDX

Capital Analysts LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 69,014 shares of the medical instruments supplier’s stock after buying an additional 5,222 shares during the period. Capital Analysts LLC’s holdings in Becton, Dickinson and Company were worth $13,394,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Brandes Investment Partners LP grew its holdings in shares of Becton, Dickinson and Company by 6.7% during the 4th quarter. Brandes Investment Partners LP now owns 1,229,707 shares of the medical instruments supplier’s stock worth $238,651,000 after purchasing an additional 77,104 shares in the last quarter. Alteri Wealth LLC grew its holdings in shares of Becton, Dickinson and Company by 9.0% during the 4th quarter. Alteri Wealth LLC now owns 1,625 shares of the medical instruments supplier’s stock worth $315,000 after purchasing an additional 134 shares in the last quarter. Focus Partners Advisor Solutions LLC grew its holdings in shares of Becton, Dickinson and Company by 34.5% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 7,797 shares of the medical instruments supplier’s stock worth $1,513,000 after purchasing an additional 1,999 shares in the last quarter. Everett Harris & Co. CA lifted its position in shares of Becton, Dickinson and Company by 0.3% during the 4th quarter. Everett Harris & Co. CA now owns 550,894 shares of the medical instruments supplier’s stock worth $106,912,000 after buying an additional 1,402 shares during the last quarter. Finally, Waddell & Associates LLC lifted its position in shares of Becton, Dickinson and Company by 69.0% during the 4th quarter. Waddell & Associates LLC now owns 3,169 shares of the medical instruments supplier’s stock worth $615,000 after buying an additional 1,294 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $152.05 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $41.90 billion, a PE ratio of 38.49, a P/E/G ratio of 10.62 and a beta of 0.22. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a 50-day moving average price of $150.53 and a two-hundred day moving average price of $174.85.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analyst Weigh In

BDX has been the subject of several recent analyst reports. Argus dropped their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Barclays upped their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Piper Sandler dropped their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $183.64.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,913 shares of company stock valued at $426,806 in the last ninety days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.